Warning: mysqli_query(): (HY000/1): Can't create/write to file '/tmp/#sql_4f7_1.MYI' (Errcode: 28 - No space left on device) in /home/mmahotstuff3/public_html/wp-includes/wp-db.php on line 1924
Allergan plc (AGN) EPS Estimated At $3.97 - Money Making Articles Hot Stuff

Allergan plc (AGN) EPS Estimated At $3.97

October 14, 2018 - By Pete Kolinski

Allergan plc (NYSE:AGN) LogoInvestors sentiment increased to 2 in Q2 2018. Its up 1.50, from 0.5 in 2018Q1. It increased, as 2 investors sold Allergan plc shares while 1 reduced holdings. 3 funds opened positions while 3 raised stakes. 69,030 shares or 10.85% less from 77,429 shares in 2018Q1 were reported.
Whittier Of Nevada invested in 0% or 21 shares. Whittier reported 0.02% of its portfolio in Allergan plc (NYSE:AGN). Mitchell Mcleod Pugh & Williams owns 3,935 shares for 0.46% of their portfolio. 2,130 are held by Cubic Asset Management Ltd Liability Corp. 43,335 are owned by Grassi Inv. Callahan Advsrs Lc reported 15,343 shares. Staley Capital Advisers holds 0.02% or 1,400 shares in its portfolio. Gemmer Asset Management Limited Liability Company reported 117 shares or 0.01% of all its holdings.

Analysts expect Allergan plc (NYSE:AGN) to report $3.97 EPS on November, 7.They anticipate $0.18 EPS change or 4.34 % from last quarter’s $4.15 EPS. AGN’s profit would be $1.35B giving it 11.54 P/E if the $3.97 EPS is correct. After having $4.42 EPS previously, Allergan plc’s analysts see -10.18 % EPS growth. The stock increased 0.58% or $1.06 during the last trading session, reaching $183.28. About 2.15M shares traded or 19.25% up from the average. Allergan plc (NYSE:AGN) has declined 17.68% since October 14, 2017 and is downtrending. It has underperformed by 33.30% the S&P500.

Allergan plc (NYSE:AGN) Ratings Coverage

Among 11 analysts covering Allergan (NYSE:AGN), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Allergan had 16 analyst reports since April 16, 2018 according to SRatingsIntel. As per Tuesday, June 12, the company rating was maintained by Bank of America. As per Tuesday, May 1, the company rating was maintained by Bank of America. Citigroup maintained Allergan plc (NYSE:AGN) rating on Tuesday, April 24. Citigroup has “Buy” rating and $200 target. Mizuho maintained the stock with “Hold” rating in Wednesday, May 30 report. Wells Fargo maintained the stock with “Outperform” rating in Tuesday, May 1 report. Wells Fargo maintained the shares of AGN in report on Thursday, August 23 with “Outperform” rating. The rating was maintained by Piper Jaffray with “Hold” on Thursday, May 31. The rating was maintained by Credit Suisse on Thursday, May 3 with “Outperform”. Cowen & Co maintained it with “Buy” rating and $25500 target in Monday, April 16 report. Raymond James maintained the stock with “Outperform” rating in Monday, September 17 report.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $62.21 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women??s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer??s disease.

More notable recent Allergan plc (NYSE:AGN) news were published by: Seekingalpha.com which released: “FDA OKs Paratek’s sarecycline for acne” on October 02, 2018, also Prnewswire.com with their article: “Allergan to Report Third Quarter 2018 Earnings and Host Conference Call and Webcast” published on October 01, 2018, Seekingalpha.com published: “Allergan announces FDA acceptance of supplemental new drug application for VRAYLAR” on September 26, 2018. More interesting news about Allergan plc (NYSE:AGN) were released by: Seekingalpha.com and their article: “Allergan to acquire Bonti for $195M” published on September 14, 2018 as well as Benzinga.com‘s news article titled: “JMP: Changing Competitive Landscape Makes Revance Less Appealing” with publication date: September 17, 2018.

Allergan plc (NYSE:AGN) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:



Warning: mysqli_query(): (HY000/1): Can't create/write to file '/tmp/#sql_4f7_1.MYI' (Errcode: 28 - No space left on device) in /home/mmahotstuff3/public_html/wp-includes/wp-db.php on line 1924
>